中國石化冀成世界領先氫能公司 目標至2025年加氫能力每年達12萬噸
中國石化公布,實施氫能中長期發展戰略,加快打造中國第一氫能公司,遠期力爭成為世界領先氫能公司的發展目標。公司將按照「加氫引領、綠氫示範、雙輪驅動、助力減碳」的思路,聚焦氫能交通和綠氫煉化兩大領域,大力發展氫能一體化業務,引領氫能產業鏈高質量發展。
公司計劃到2025年建成加氫能力每年12萬噸,全力滿足消費終端的加氫需求;並在現有煉化和煤化工製氫的基礎上,大力發展可再生電力製氫,進一步擴大清潔綠色氫氣生產利用規模,並抓好綠電制氫重大示範項目佈局建設,逐步在煉化領域替代化石原料製氫,推動工業領域深度脫碳。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.